Avelumab and Merkel Cell Carcinoma: Examining the Biological Plausibility of Causation
From General Health Education to Occupational Exposure Concerns
The legacy of general health and science communication has long emphasized broad, accessible education on wellness, disease prevention, and therapeutic advances. Within this tradition, public understanding of pharmaceutical interventions has been framed around benefits and risks in a population-level context, often focusing on common conditions and widely used treatments. This heritage provides a foundation for examining how specialized medical products may intersect with occupational environments, where exposure patterns differ from typical clinical use. Transitioning from this general health perspective, attention now turns to occupational exposure concerns. In mass production settings, workers may encounter pharmaceutical agents during manufacturing, handling, or disposal, creating distinct risk profiles. Avelumab, a monoclonal antibody used in oncology, represents one such agent where workplace exposure warrants careful consideration. The biological plausibility of avelumab-related Merkel cell carcinoma risk involves understanding how immune checkpoint inhibition could theoretically influence tumor surveillance mechanisms. However, this section does not delve into disease-specific mechanistic claims. Instead, it establishes the pivot from broad health education to the specific occupational context where avelumab exposure may occur, highlighting the need for rigorous exposure assessment and risk management in production environments without making causal assertions.
Understanding Avelumab: Mechanism and Therapeutic Use
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/;https://pubmed.ncbi.nlm.nih.gov/33439294/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the biological plausibility of avelumab causing or contributing to Merkel cell carcinoma must be examined separately from its therapeutic use, as the drug is indicated to treat MCC, not to induce it.
Etiology of Merkel Cell Carcinoma and Avelumab's Role
Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 immune checkpoint inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing T-cell responses against tumor cells (https://pubmed.ncbi.nlm.nih.gov/34445385/). In the context of MCC treatment, avelumab is intended to activate the immune system to attack existing cancer cells. However, checkpoint inhibitors are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can include a range of inflammatory conditions, but there is no established mechanistic pathway by which avelumab directly causes de novo Merkel cell carcinoma. Instead, the drug is used to treat MCC, and the reported adverse effects are primarily immune-mediated toxicities, such as hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/).
Evaluating the Evidence for Causation
The risk narrative regarding avelumab and MCC causation must consider that the drug is a treatment for the disease, not a known trigger. The evidence indicates that avelumab is used in patients who already have metastatic MCC, and its efficacy is measured by response rates, with up to 62% response rates to PD-1/PD-L1 inhibition in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). For patients who are refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab have been explored, with some patients responding (https://pubmed.ncbi.nlm.nih.gov/33439294/). This suggests that avelumab does not cause MCC but rather is a therapeutic agent that may fail in some patients, leading to disease progression. Regarding adequacy of warnings, the approved labeling for avelumab includes information about immune-related adverse events, but there is no evidence in the provided snippets that avelumab carries a warning about causing Merkel cell carcinoma. Since the drug is indicated for MCC treatment, the risk of developing MCC from avelumab exposure is not biologically plausible based on current understanding.
Timeline and Clinical Observations
The timeline between exposure and documented harm is relevant only in the context of treatment failure or irAEs, not causation of MCC. For example, hypercalcaemia due to sarcoidosis reactivation occurred during avelumab treatment and resolved with corticosteroids, allowing continuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that adverse events can occur on a timeline of weeks to months after starting avelumab, but these are immune-related effects, not the induction of a new cancer. Causation-related considerations for affected patients would focus on whether avelumab could worsen an existing MCC or trigger a new primary MCC. The evidence does not support a causal link. Instead, avelumab is associated with immune activation that can lead to irAEs, but not to the development of MCC. The biological plausibility of avelumab causing MCC is low because the drug targets PD-L1 to enhance anti-tumor immunity, which would theoretically reduce the risk of cancer, not increase it. However, in rare cases, immune checkpoint inhibitors have been associated with atypical responses, such as hyperprogression, but this is not specifically documented for avelumab and MCC in the provided evidence.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, the evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is a treatment for metastatic MCC, and its mechanism of action enhances anti-tumor immunity. There is no established mechanistic pathway by which avelumab induces de novo MCC.
What are the known adverse effects of avelumab?
Avelumab is associated with immune-related adverse events (irAEs) such as hypercalcaemia due to sarcoidosis reactivation, as reported in clinical studies (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are immune-mediated toxicities, not the induction of new cancers.
Is there a biological plausibility for avelumab causing MCC?
The biological plausibility is low. Avelumab blocks PD-L1 to activate T-cells against tumors, which would theoretically reduce cancer risk. No evidence links avelumab to the development of MCC.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.